Skip to main content

Advertisement

SpringerLink
Log in

Acute Exacerbations of Chronic Bronchitis

A Pharmacoeconomic Review of Antibacterial Use

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Chronic bronchitis is a common problem affecting a large proportion of the adult population. People with chronic bronchitis are subject to recurrent attacks of bronchial inflammation called acute exacerbations of chronic bronchitis (AECBs). In patients with AECBs, symptoms may worsen due to a bacterial infection; the exacerbation is then known as an acute bacterial exacerbation of chronic bronchitis (ABECB). ABECBs are thought to be controllable through the use of antibacterial agents.

In this paper we review current evidence on the cost of chronic bronchitis and AECBs, the cost effectiveness of antibacterials in the management of ABECB, and the factors that may affect the cost-effectiveness of antibacterials in the management of ABECB. We find that the number of economic evaluations conducted in this area is small. Of the few economic evaluations that have been conducted there has been only one prospective economic evaluation based on a clinical trial. The remainder are simple decision analysis-based modelling studies or retrospective database studies.

Our principle findings are as follows: (i) a key factor affecting the cost-effective use of antibacterials in the management of ABECB is the definitive diagnosis of the condition. Unfortunately, diagnosing a bacterial cause of an AECB is difficult, which presents problems in ensuring that antibacterials are not prescribed unnecessarily; (ii) current evidence suggests but does not prove that use of more effective but more costly first-line antibacterials may be relatively cost effective and may minimise overall expenditure by reducing the high costs associated with treatment failure; (iii) chronic bronchitis and AECB have a significant and negative physical and psychological effect on health-related quality of life.

In conclusion, the small number of economic evaluations conducted in this area, coupled with the nature of the design of these studies, precludes a definitive statement recommending which specific antibacterial should be preferred on cost-effectiveness grounds for the management of ABECB. On the basis of our findings we suggest some topics for further research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Fig. 1
Table VII
Fig. 2
Table VIII

Similar content being viewed by others

References

  1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77–121

    Google Scholar 

  2. Pechere JC, Lacey L. Optimising economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemopther 2000; 45 T2: 19–24

    Article  Google Scholar 

  3. Ball P, Harris JM, Lowson D, et al. Acute infective exacerbations of chronic bronchitis: A study of outcome by clinical parameters. Q J Med 1995; 88: 61–8

    CAS  Google Scholar 

  4. Niederman MS, McCombs JS, Unger AN, et al. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999; 21: 576–91

    Article  PubMed  CAS  Google Scholar 

  5. Ball P, Tillotson G, Wilson R. Chemotherapy for chronic bronchitis: controversies. Presse Med 1995; 24: 189–94

    PubMed  CAS  Google Scholar 

  6. Connors AF, Dawson NV, Tomas C. Outcomes following acute exacerbations of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996; 154: 959–67

    PubMed  Google Scholar 

  7. Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother 1999; 43 Suppl. A: 97–105

    Article  PubMed  CAS  Google Scholar 

  8. Woodhead M, Gialdroni Grassi G, Huchon GJ, et al. Use of investigations in lower respiratory tract infections in the community: a European survey. Eur Respir J 1996; 9: 156–60

    Article  Google Scholar 

  9. Guest J, Morris A. Community acquired lower respiratory tract infections: the annual cost to the National Health Service. Br J Med Econ 1996; 10: 263–73

    Google Scholar 

  10. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204

    PubMed  CAS  Google Scholar 

  11. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995; 273: 957–60

    Article  PubMed  CAS  Google Scholar 

  12. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995 Aug; 108 Suppl.: S43–52

    Google Scholar 

  13. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: state of the art. Am J Med 1991; 91 Suppl. 6A: S87–92

    Article  Google Scholar 

  14. McGuire A, Irwin DE, Fenn P, et al. The excess cost of acute exacerbations of chronic bronchitis in patients over age 45 in England and Wales. Value Health. In press

  15. Torrance G, Walker V, Grossman R, et al. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. PharmacoEconomics 1999; 16: 499–520

    Article  PubMed  CAS  Google Scholar 

  16. Grossman RF, Mukherjee J, Vaughan D, et al. A1-year community-based health economic study of ciprofloxacin vs. usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 1998; 113: 131–41

    CAS  Google Scholar 

  17. Hunt SM, McEwen J, McKenna SF. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985; 4: 185–8

    Google Scholar 

  18. Jones PW, Quirk FM, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation: the St George’s Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321–7

    PubMed  CAS  Google Scholar 

  19. Feeny D, Furlong W, Boyle M, et al. Multi-attribute health status classifications systems: Health Utilities Index. Pharmacoeconomics 1995; 7 (6): 490–502

    Article  PubMed  CAS  Google Scholar 

  20. Destache CJ, Dewan N, O’Donohue WJ, et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 43 Suppl. A: 107–13

    Article  PubMed  CAS  Google Scholar 

  21. Backhouse R, Shakespeare A, Hutton J. Economic evaluation of alternative antibiotic regimens in the management of acute exacerbations of chronic bronchitis. Br J Med Econ 1995; 8: 11–25

    Google Scholar 

  22. van Barlingen HJ, Nuijten MJ, Volmer T, et al. Model to evaluate the cost-effectiveness of different antibiotics in the management of acute bacterial exacerbations of chronic bronchitis in Germany. J Drug Assess 1998; 1: 695–711

    Google Scholar 

  23. Health Technology Brief 004 January 2000 [online]. Available from URL: http://www.hta.nhsweb.nhs.uk/htb.htm

  24. Coast J, Smith RD, Millar MR. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Econ 1996; 5: 217–26

    Article  PubMed  CAS  Google Scholar 

  25. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995; 99 Suppl. 6B: S3–7

    Article  Google Scholar 

  26. de Groot R, Dzoljic-Danilovic G, van Klingeren B, et al. Antibiotic resistance in Haemophilus influenzae: mechanisms, clinical importance and consequences of therapy. Eur J Pediatr 1991; 150: 534–46

    Article  PubMed  Google Scholar 

  27. Davies TA, Pankuch GA, Dewasse BE, et al. In vitro development of resistance to five quinolones and amoxicillin clavulanate in Streptococcus pneumonaie. Antimicrob Agents Chemother 1999; 43: 1177–82

    PubMed  CAS  Google Scholar 

  28. Nicolson P, Anderson P. The patient’s burden: physical and psychological effects of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 2000; 45 T2: 25–32

    Article  Google Scholar 

  29. Grossman RF. Cost-effective therapy for acute exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15: 71–81

    Article  PubMed  CAS  Google Scholar 

  30. Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbations of chronic obstructive lung disease: factors associated with poor treatment outcomes. Chest. In press

  31. Lovering A, Feeney R, Brown I, et al. Resource utilisation for people hospitalised with community-acquired chest infection [abstract]. Eur Resp J 1997; 10 Suppl. 25: S1733

    Google Scholar 

  32. Lovering AM, MacGowan AP, Anderson P, et al. Epidemiology and resource utilisation for patients hospitalised for lower respiratory tract infection. Clin Microbiol Infect 2001; 7: 666–70

    Article  PubMed  CAS  Google Scholar 

  33. Cockburn J, Gibberd RW, Reid AL, et al. Determinants of noncompliance with short-term antibiotic regimens. BMJ 1987; 295: 814–8

    Article  PubMed  CAS  Google Scholar 

  34. Braithwaite A, Pechere JC. Pan-European survey of patients’ attitudes to antibiotics and antibiotic use. J IntMed Res 1996; 24: 229–38

    Google Scholar 

Download references

Acknowledgements

There were no sources of funding used to assist in the preparation of this manuscript and there were no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Economics, City University, Northampton Square, London, EC1V 0HB, UK

    Stephen Morris

  2. Fourth Hurdle Consulting Limited, London, UK

    Pippa Anderson

  3. Epidemiology Division, Ingenix Pharmaceutical Services, North Carolina, USA

    Debra E. Irwin

Authors
  1. Stephen Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pippa Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Debra E. Irwin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen Morris.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morris, S., Anderson, P. & Irwin, D.E. Acute Exacerbations of Chronic Bronchitis. Pharmacoeconomics 20, 153–168 (2002). https://doi.org/10.2165/00019053-200220030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200220030-00002

Keywords

Search

Navigation